CLOs on the Move

Arraystar

www.arraystar.com

 
Arraystar is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Kaleo

Kaléo is dedicated to inventing, manufacturing and commercializing life-transforming products that empower patients and families to live fuller, bolder lives. We are committed to developing solutions that support the healthcare provider-patient relationship, improving access to our products.

ProgenyHealth

ProgenyHealth is a leading provider of care management solutions for premature and medically complex newborns. Our program promotes appropriate utilization, improves access, educates family members and reduces costs. Progeny`s foundation is built on evidence-based best practices, timely communication, and ongoing collaboration with clients and providers. This proactive approach has resulted in our expansion into 50 states and significant and reproducible cost savings for our clients.

Life Care Ctr

Life Care Ctr is a Fitzgerald, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Elorac Inc.

Elorac Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Vernon Hills, IL. To find more information about Elorac Inc., please visit www.eloracpharma.com

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.